



**Correction to: Lindstrom r and Kim t.
Ocular permeation and inhibition of retinal
inflammation: an examination of data and expert
opinion on the clinical utility of nepafenac.
Curr Med res Opin 2006; 22(2): 397–404.
doi:10.1185/030079906X89775**

To cite this article: (2006) Correction to: Lindstrom r and Kim t. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med res Opin 2006; 22(2): 397–404. doi:10.1185/030079906X89775, Current Medical Research and Opinion, 22:6, 1237-1237, DOI: [10.1185/030079906X115766](https://doi.org/10.1185/030079906X115766)

To link to this article: <https://doi.org/10.1185/030079906X115766>



Published online: 25 May 2006.



Submit your article to this journal [↗](#)



Article views: 94



View related articles [↗](#)

Erratum

Correction to: Lindstrom R and Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. *Curr Med Res Opin* 2006; 22(2): 397-404. doi:10.1185/030079906X89775

The following corrections are required to the online and print versions of this paper.

Page 401: The labelling on Figures 3 and 4 should be corrected to read: Ketorolac 0.5%. Corrected versions of the two figures appear below.




Figure 4.




Figure 5.

CrossRef links are available in the online published version of this paper:
<http://www.cmrojournal.com>
 Paper CMRO-3293E_3, Accepted for publication: 11 May 2006
 Published Online: 25 May 2006
 doi:10.1185/030079906X115766